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Abstract
Background: The majority of people living with HIV require antiretroviral therapy (ART) for controlling viral
replication, however there are rare HIV controllers who spontaneously and durably control HIV in the absence of
treatment. Understanding what mediates viral control in these individuals has provided us with insights into the
immune mechanisms that may be important to induce for a vaccine or functional cure for HIV. To date, few African
elite controllers from high incidence settings have been described. We identified virological controllers from the
CAPRISA 002 cohort of HIV-1 subtype C infected women in KwaZulu Natal, South Africa, two (1%) of whom were
elite controllers. We examined the genetic, clinical, immunological and virological characteristics of these two elite
HIV controllers in detail, to determine whether they exhibit features of putative viral control similar to those
described for elite controllers reported in the literature.
Case presentation: In this case report, we present clinical features, CD4+ T cell and viral load trajectories for two
African women over 7 years of HIV infection. Viral load became undetectable 10 months after HIV infection in Elite
Controller 1 (EC1), and after 6 weeks in Elite Controller 2 (EC2), and remained undetectable for the duration of
follow-up, in the absence of ART. Both elite controllers expressed multiple HLA Class I and II haplotypes previously
associated with slower disease progression (HLA-A*74:01, HLA-B*44:03, HLA-B*81:01, HLA-B*57:03, HLA-DRB1*13).
Fitness assays revealed that both women were infected with replication competent viruses, and both expressed
higher mRNA levels of p21, a host restriction factor associated with viral control. HIV-specific T cell responses were
examined using flow cytometry. EC1 mounted high frequency HIV-specific CD8+ T cell responses, including a B*81:
01-restricted Gag TL9 response. Unusually, EC2 had evidence of pre-infection HIV-specific CD4+ T cell responses.
Conclusion: We identified some features typical of elite controllers, including high magnitude HIV-specific
responses and beneficial HLA. In addition, we made the atypical finding of pre-infection HIV-specific immunity in
one elite controller, that may have contributed to very early viral control. This report highlights the importance of
studying HIV controllers in high incidence settings.
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Background
There is substantial variability in HIV control and
disease progression among people living with HIV. Indi-
viduals can either resist infection despite repeated HIV
exposure, maintain low levels of virus without antiretro-
viral therapy (ART) (HIV controllers), or control HIV
replication to an undetectable level [elite controllers
(ECs)] [1]. Understanding the mechanisms that mediate
control in these individuals may assist with developing
an effective HIV vaccine or cure. However, comprehen-
sive studies on ECs from developing countries with high
disease burden are lacking, and since the introduction of
universal treatment, opportunities to detect and study
these unique individuals are diminishing.
Elite controllers serve as a model for determining
factors associated with the protection against HIV. Clinical,
immunological, host genetic and virological characteristics
have been explored [1] to determine whether elite control
is due to a lack of HIV infection of CD4 target cells,
replication-defective HIV variants, effective viral control by
the host immune system, and/or reduced inflammation
with a smaller pool of susceptible CD4 cells [2]. Studies on
ECs show that viral control is not solely due to deficient
virus, but rather due to host immune responses controlling
HIV replication [1–3].
We investigated a longitudinal cohort of South African
women who were HIV-uninfected, HIV controllers or
HIV progressors. Two ECs were identified and examined
in detail for clinical, immunological, host genetic and
virological characteristics to understand the mechanisms




Women seroconverting in the Centre of the AIDS
Programme of Research in South Africa (CAPRISA)
HIV prevention studies since 2004, were enrolled into
the CAPRISA 002 acute infection cohort study [4, 5].
Controllers were identified and classified either as vir-
aemic or elite, according to their plasma viral load (VL)
in the absence of ART [6]. Briefly, viraemic controllers
were defined as those with sustained measurements of
50–2000 RNA copies/ml after six months of infection,
while elite controllers were those with consecutive
undetectable HIV RNA measurements for six months or
more. The two elite controllers described in this study
had participated in the CAPRISA 004 tenofovir microbi-
cide gel trial [7]. This trial took place between May 2007
and March 2010, and both participants were randomized
to the placebo arm. After enrollment into CAPRISA
004, participants had monthly follow-up visits for up to
24 months. PBMC were stored at pre-selected time-
points (3, 12 and 24 months). Two HIV rapid antibody
tests were performed at monthly visits. Stored plasma,
available from prior study visits, was tested by means of
RNA PCR, so as to identify the window period for HIV
infection and calculate the estimated date of infection.
This was defined as two weeks prior to an RNA PCR–
positive result if rapid HIV antibody test–negative on
the same visit, or as the mid-point between the last HIV
negative and first HIV positive antibody test, if no stored
plasma was available.
Cellular immunology
HIV-specific T-cell responses within peripheral blood
mononuclear cell (PBMC) were measured using pools of
overlapping peptides spanning Gag, Pol, and Nef of
HIV-1 subtype C, as described [8]. IFN-γ ELISPOT as-
says were used to map epitopes that were predicted from
study participants’ human leukocyte antigen (HLA)
profiles, as described [8]. T-cell activation and HIV-
specific cytokine responses were measured at time-
points pre- and post-infection using flow cytometry. The
T-cell activation panel included a viability dye (Vivid)
and antibodies to detect CD3, CD4, CD8, HLA-DR and
CD38. For the evaluation of HIV-specific responses, cells
were stained with Vivid, surface-stained with anti-CD4,
CD8, CD14 and CD19 (the latter two being exclusion
markers), followed by intracellular staining with CD3,
IFN-γ, TNF-α and IL-2. Samples were acquired on a BD
Fortessa and analysed using FlowJo (TreeStar). Cells
were gated on singlets, followed by live CD3+ lympho-
cytes, and then CD4+ or CD8+ subsets. A positive
cytokine response was defined as at least twice the back-
ground unstimulated sample. Cytokine responses are
presented as the background-subtracted total response,
representing the frequency of CD4+ or CD8+ T cells
producing any of the three cytokines, with the exception
of TNF-α-single positive cells, that were excluded due to
high TNF-α background responses.
Antibody neutralization
Plasma neutralization breadth was determined at 2, 3
and 4 years post-infection for each EC against a panel of
18 heterologous viruses, including 6 subtype C, 6
subtype A and 6 subtype C viruses. The JC53bl-13
(TZM-bl) and 293 T cell lines were obtained through
the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu
and Tranzyme Inc. and Dr. Andrew Rice respectively.
Both cell lines were cultured in DMEM containing 10%
heat-inactivated FBS and 50 μg/ml gentamicin. Cell
monolayers were disrupted at confluency by treatment
with 0.25% trypsin in 1 mM EDTA. Env-pseudotyped vi-
ruses were obtained by co-transfecting Env plasmids
with pSG3ΔEnv [9] using FuGENE transfection reagent
(Roche) as previously described [10]. Neutralization was
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measured as described by a reduction in luciferase gene
expression after single-round infection of JC53bl-13 cells
with Env-pseudotyped viruses [10]. Titers were calcu-
lated as the reciprocal plasma dilution (ID50) causing
50% reduction of relative light units (RLU).
Host genetics
HLA and other host genetic factors associated with viral
control in published studies were examined, namely C-C
chemokine receptor type 5 (CCR5) and cyclin-dependent
kinase inhibitor (CDKN1A-p21) genes. HLA typing was
performed as described [11]. mRNA expression levels of
CCR5 and p21 were measured using real-time PCR
(Roche LightCycler 480 v1.5), with GAPDH as a house-
keeping control.
Virology
Gag and nef sequences from acute infection were gener-
ated from plasma RNA, as described [12], and compared
to the subtype-C 2004 consensus (www.hiv.lanl.gov)
using EpitopeMatcher. Primary isolate and Gag-Pro-
mediated replication capacity was determined, as
described [13]. Gag DNA copy number was quantified
using digital droplet PCR (ddPCR) [14].
Results
Clinical
We studied 233 women, median age 25 years at enroll-
ment, contributing 906 person-years of ART-naïve
follow-up (median 3.8 years). Ten women (4.3%) were
identified as viraemic controllers, and two (1%) as ECs
(EC1 and EC2). Controllers were followed for a median
of 6.6 years post-infection (ART-naïve for a median
5.4 years).
EC1, a 28-year-old woman, presented with a past
medical history of recurrent urinary tract infections,
tonsillitis, rashes and sexually transmitted infections.
Peak VL was 12,902 copies/ml at 23 days post-infection,
then dropped to an undetectable level by 10 months and
remained suppressed for over 7 years without ART
(Fig. 1a). The CD4 count and CD4:CD8 ratio steadily
increased throughout follow-up.
EC2, a 38-year-old woman, presented with a past
medical history of hypertension and chronic pelvic pain
following a caesarean section. Peak VL was 1954 copies/
ml at 14 days post-infection (Fig. 1b), became undetect-
able by 6 weeks and remained suppressed for over
6 years, without ART. The CD4 count steadily increased
throughout follow-up, while the CD4:CD8 ratio
remained above one.
Immunology
T-cell activation levels for EC1 were highest at peak
viraemia, declined by 5 months post-infection, and
remained low during viral suppression (Fig. 1c). The
proportion of activated CD8+ T-cells was higher than
CD4+ T-cells. EC2 had considerably lower levels of T-
cell activation, and peak CD8+ activation levels also
coincided with peak VL, declining during viral suppres-
sion (Fig. 1d). T-cell activation for these two ECs was as
low as measured for 23 HIV-uninfected individuals rather
than for 18 HIV progressors at 5 years post-infection
(CD4: 1.8% vs 1.5% and 6.8%; CD8: 5.4% vs 3.7% and
22.7%, respectively) (Additional file 1: Figure S1).
EC1 elicited high magnitude CD8+ T-cell responses
secreting IFN-γ, TNF-α and IL-2 against Gag and Nef,
with moderate responses to Pol over the first year of
infection (Fig. 1e). Lower magnitude CD4+ T-cell re-
sponses were mounted to Gag and Pol. T-cell responses
declined over 5 years of viral suppression, but remained
detectable. Using the IFN-γ ELISPOT assay, the Gag
response was mapped to the HLA-B*81:01-restricted
TL9 epitope.
EC2 elicited a weaker CD8+ Gag response at 1 year
post-infection, that declined over the follow-up period,
and low magnitude CD4+ T-cell responses to Gag
and Pol were detected at 1 and 5 years post-infection
(Fig. 1f ). Intriguingly, CD4+ T-cell responses to Gag
and Pol were detected at several time points in the
year pre-infection, and confirmed in a repeat assay
(Additional file 1: Figure S2). However, these re-
sponses were absent at 13 months pre-infection. We
found no evidence of detectable virus at any of the
pre-infection time points using a sensitive quantitative
ddPCR assay.
We also investigated plasma neutralization activity
against subtype C, B and A viruses in the two ECs at
2, 3 and 4 years post-infection (Additional file 1:
Figure S3). EC1 developed neutralizing antibodies to
subtype C and A viruses by 2 years post-infection,
which waned by 4 years. In contrast, for EC2, no
neutralizing antibodies were detected at years 2 and 3
post-infection, while weak neutralization activity to
several viruses emerged at year 4.
Host genetics
HLA alleles previously shown to associate with slower
disease progression were identified within the ECs
(Additional file 2: Table S1) [15]. EC1 possessed protective
alleles HLA-B*44:03, HLA-B*81:01 and HLA-DRB1*13,
while EC2 expressed HLA-A*74:01, HLA-B*57:03 and
HLA-DRB1*13.
Higher mRNA expression of the cell-intrinsic inhibitor
of HIV reverse transcription, p21, was observed among
10 controllers compared to 30 HIV-uninfected partici-
pants (median relative ratio 21.8 vs. 13.7, p = 0.03,
Additional file 1: Figure S4A) [16], with ECs expressing
amongst the highest levels. For CCR5 expression,
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controllers had a trend towards lower expression com-
pared to progressors (median relative ratio 12.7 vs. 7.6,
p = 0.06) (Additional file 1: Figure S4B) [17].
Virology
Viral sequencing of EC1 at 25 days post-infection




Fig. 1 Characterization of HIV elite controllers (ECs). Clinical profiles are presented for EC1 (a) and EC2 (b) over 7 years of HIV infection. Longitudinal
measurements of CD4, viral load (VL) and CD4:CD8 ratio are represented as blue (left axis), red (right axis) and black, respectively. Green arrows indicate
time-points selected for immune assays. T-cell activation profiles for EC1 (c) and EC2 (d) are shown for CD4+ and CD8+ T-cells. CD8+ T-cell activation
is indicated in red and CD4+ T-cell activation in blue. Dashed lines indicate the frequency of CD38 expression and solid lines HLA-DR expression for
each subset. HIV-specific T-cell responses for EC1 (e) and EC2 (f) represented as intracellular cytokine responses (IFN-γ, TNF-α and IL-2) to Gag (circle),
Nef (square) and Pol (triangle) are indicated (background subtracted). CD4 (blue lines) and CD8 (red lines) responses are indicated. The horizontal black
dashed line indicates the cut-off for a positive response (0.05% of T-cells). The grey shaded area on the graphs indicates where VL was lower than the
detectable limit of the assay. The red vertical dashed line in all graphs indicates the estimated time of HIV infection
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B*81:01-targeted viral epitopes when compared to a
subtype-C consensus sequence. B*44:03-targeted epi-
topes contained three mismatches, two in Gag and one
in Nef. The replication capacity of the EC1 isolate was
comparable to the median of 34 primary isolates from
the same cohort (data not shown).
For EC2, polymorphisms in predicted epitopes for
B*57:03 and B*14:01 alleles were examined at 21 days
post-infection. B*57:03-targeted epitopes showed two
Gag polymorphisms associated with immune escape,
namely the IW9 (A146P polymorphism) and TW10
epitope (T242 N variant). However, the Gag-Pro-
mediated replication capacity of EC2 recombinant virus
was not impaired and comparable to the median of 71
Gag-Pro-NL4–3 recombinants from the same cohort
(data not shown).
Discussion and conclusions
In this cohort of HIV-1 subtype-C infected South
African women, the prevalence of controllers was con-
sistent with 28 cohorts across Europe, Canada, Australia
and sub-Saharan Africa [18]. Our findings confirm that
elite control is a heterogeneous phenotype with multi-
factorial mechanisms [1, 6, 18]. The two ECs identified
had detectable viremia within 10 months of infection,
but were able to control the virus thereafter. Further-
more, they showed low levels of T-cell activation,
specific cytokine T-cell responses to HIV antigens, and
no evidence for reduced viral replication capacity. Host
restriction factors examined here were consistent with
previous studies, where ECs expressed higher levels of
p21 compared to HIV-uninfected donors, and lower
levels of CCR5 compared to HIV progressors.
Our results suggest that one mechanism responsible
for elite control is a potent HIV-specific host response
[2]. For one EC, high magnitude CD8+ responses, in-
cluding an immunodominant B*81:01 Gag response,
shown to be beneficial [15], likely contributed to viral
control. In contrast, the other EC had detectable CD4+
responses to Gag and Pol pre-infection. We were unable
to detect any evidence of virus in plasma at the ‘pre-in-
fection’ time points, using an ultrasensitive assay.
HIV-specific responses in the absence of sustained viral
infection could have resulted from either abortive infec-
tion, or contained local infection foci that did not spread
beyond the site of transmission, and represent ‘immune
footprints’ of HIV exposure. HIV-specific responses in
the absence of HIV infection have been described in
HIV-exposed, but uninfected participants in the iPrEx
pre-exposure prophylaxis trial, some of whom mounted
high magnitude HIV-specific CD4+ and CD8+ responses
[19]. Although the iPrEx study did not determine
whether these responses modified the disease course in
HIV seroconvertors, the presence of certain HIV-specific
responses associated with reduced HIV infection risk [20].
It is possible that pre-infection CD4+ T cell responses in
EC2 could have restricted viral replication and contributed
to spontaneous control, leading to her elite controller
phenotype. Additional studies would be required to inves-
tigate this further. Given the potentially high levels of HIV
exposure in high incidence settings, it may be interesting
to determine whether HIV-specific responses in the
absence of HIV infection are more widespread, and could
impact HIV infection risk or disease course.
We found heterogenous HIV neutralization activity in
the two elite controllers, with neutralizing antibodies
waning by year 4 in EC1, and weak responses emerging
only at year 4 in EC2. It is thus unlikely that these
responses contributed to HIV control. This is consistent
with studies demonstrating lower neutralizing antibody
titers in ECs compared to viremic patients [21, 22]. In
contrast, a recent report described multiple potent
broadly neutralizing antibodies detected in an elite con-
troller after more than 20 years of HIV infection [23].
Upregulation of p21 in T-cells within ECs compared to
HIV-uninfected or progressors has been observed previ-
ously [16]. p21 mediates control by blocking cyclin-
dependent kinases, a group of host molecules supporting
different HIV-1 replication steps [16]. The mechanism of
action for the CCR5 gene has been well-described, i.e.
elevated levels associate with loss of control by providing
increased co-receptors to the virus [17]. Our study was
limited in that we did not test the full breadth of host fac-
tors that could potentially have influenced the viral control
in the ECs we studied. The ligand for CCR5, CCL3, has
been implicated in HIV disease progression [24]. There is
also evidence of polymorphisms in APOBEC3G and
SAMHD1 contributing to control in ECs [25, 26]. Further
studies examining these and other restriction factors may
shed more light on the elite controller phenotype.
In conclusion, in this case report we provide a detailed
description of two elite controllers from a high burden
HIV setting in South Africa, who displayed both typical
and atypical features of elite control. Our results high-
light the importance of studying HIV control in high
incidence settings, where new insights may be gained
into mechanisms of durable viral control.
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Moosa et al. BMC Infectious Diseases  (2018) 18:54 Page 5 of 7
Abbreviations
IFN-γ: Interferon-gamma; ART: Antiretroviral therapy; CAPRISA: Centre of the
AIDS Programme of Research in South Africa; CCR5: C-C chemokine receptor
type 5; CDKN1A-p21: Cyclin-dependent kinase inhibitor; ddPCR: Digital
droplet PCR; EC: Elite controller; ELISPOT: Enzyme-linked immunosorbent
spot; HIV: Human immunodeficency virus; HLA: Human leukocyte antigen;
IL-2: Interleukin-2; MRNA: Messenger RNA; PBMC: Peripheral blood
mononuclear cells; PCR: Polymerase chain reaction; TNF-α: tumour necrosis
factor alpha; VL: Viral load
Acknowledgments
We thank the CAPRISA 002 study team and all CAPRISA 002 study participants.
Funding
This work was supported by the National Institutes of Health (grant numbers
AI51794 and D43TW00231), Contraception Research and Development (grant
numbers GP00–08–00005-00 and PPA-09-046), National Research Foundation
(grant numbers 67385 and 96354) and South African Medical Research Council
Flagship Award (grant number MRC-RFA-UFSP-01-2013/UKZN-HIVEPI). The
funders had no role in the design of the study or collection, analysis, and
interpretation of data, or in writing the manuscript.
Availability of data and materials
All the datasets supporting the conclusions of this article are included within
the article and its supplementary files (four Figures and one Table).
Authors’ contributions
All authors participated in the analysis and description of the work presented
in this manuscript. YM, NYZ, CW, SSAK, NJG and WAB conceived the study,
participated in its design and coordination, and analyzed epidemiological
and clinical data. RFT, VR, RS, MM, MRA, PS, KG, PLM, NJG and WAB
performed experimental work and analysis. YM, RFT, VR, PLM, NJG and WAB
wrote the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval for the study was obtained from the Research Ethics
Committees of the University of KwaZulu-Natal (E013/04) and University of
Cape Town (025/2004). All participants provided written, informed consent
to participate in the study.
Consent for publication
Consent to publish was obtained from EC1 and EC2.
Competing interests
None of the authors have any competing interests to declare.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Centre for the AIDS Programme of Research in South Africa (CAPRISA),
University of KwaZulu-Natal, Durban, South Africa. 2Institute of Infectious
Disease and Molecular Medicine, Faculty of Health Sciences, University of
Cape Town, Cape Town, South Africa. 3School of Laboratory Medicine and
Medical Sciences, College of Health Sciences, University of KwaZulu-Natal,
Durban, South Africa. 4Cancer Inflammation Program, Laboratory of
Experimental Immunology, Leidos-Frederick, Incorporated, Frederick National
Laboratory for Cancer Research, Frederick, USA. 5Department of
Microbiology, National Health Laboratory Services, KZN Academic Complex,
Inkosi Albert Luthuli Central Hospital, Durban, South Africa. 6Centre for HIV
and STIs, National Institute for Communicable Diseases (NICD) of the
National Health Laboratory Service, Johannesburg, South Africa. 7HIV
Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R.
Mandela School of Medicine, University of KwaZulu-Natal, Durban, South
Africa. 8Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg, South Africa. 9Department of Epidemiology, Mailman School
of Public Health, Columbia University, New York, NY, USA.
Received: 9 July 2017 Accepted: 15 January 2018
References
1. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection:
implications for vaccine design. Expert Opin Biol Ther. 2009;9(1):55–69.
2. Saag M, Deeks SG. How do HIV elite controllers do what they do? Clin
Infect Dis. 2010;51(2):239–41.
3. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, et al. Isolation and
characterization of replication-competent human immunodeficiency virus
type 1 from a subset of elite suppressors. J Virol. 2007;81(5):2508–18.
4. Mlisana K, Werner L, Garrett NJ, McKinnon LR, van Loggerenberg F,
Passmore JA, et al. Rapid disease progression in HIV-1 subtype C-infected
south African women. Clin Infect Dis. 2014;59(9):1322–31.
5. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray CM, et
al. Establishing a cohort at high risk of HIV infection in South Africa:
challenges and experiences of the CAPRISA 002 acute infection study. PLoS
One. 2008;3(4):e1954.
6. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, et
al. Clinical outcomes of elite controllers, viremic controllers, and long-term
nonprogressors in the US Department of defense HIV natural history study.
J Infect Dis. 2009;200(11):1714–23.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C,
Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral
microbicide, for the prevention of HIV infection in women. Science.
2010;329(5996):1168–74.
8. Burgers WA, Riou C, Mlotshwa M, Maenetje P, de Assis RD, Brenchley J,
et al. Association of HIV-specific and total CD8+ T memory phenotypes
in subtype C HIV-1 infection with viral set point. J Immunol. 2009;
182(8):4751–61.
9. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody
neutralization and escape by HIV-1. Nature. 2003;422(6929):307–12.
10. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al.
HIV-1 neutralization breadth develops incrementally over 4 years and is
associated with CD4+ T cell decline and high viral load during acute
infection. J Virol. 2011;85(10):4828–40.
11. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate
partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet.
2007;39(6):733–40.
12. Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, et
al. No evidence for selection of HIV-1 with enhanced gag-protease or Nef
function among breakthrough infections in the CAPRISA 004 tenofovir
microbicide trial. PLoS One. 2013;8(8):e71758.
13. Selhorst P, Combrinck C, Ndabambi N, Ismail SD, Abrahams MR, Lacerda M,
et al. Replication capacity of viruses from acute infection drives HIV-1
disease progression. J Virol. 2017;91(8):e01806–16.
14. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, et al. Highly
precise measurement of HIV DNA by droplet digital PCR. PLoS One.
2013;8(4):e55943.
15. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control
of immunodeficiency virus replication. Nat Rev Immunol. 2008;8(8):619–30.
16. Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, et al. A cell-intrinsic
inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite
controllers. Cell Host Microbe. 2014;15(6):717–28.
17. Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell SB,
et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected
and uninfected individuals. J Immunol. 1998;161(6):3195–201.
18. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, et al. An
evaluation of HIV elite controller definitions within a large seroconverter
cohort collaboration. PLoS One. 2014;9(1):e86719.
19. Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, et
al. Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis
trial. Proc Natl Acad Sci. 2015;112(27):8379–84.
20. Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG,
Nixon DF. HIV-1 gp120 T-cell responses correspond to infection outcomes
in the global iPrEx chemoprophylaxis trial. J Acquir Immune Defic Syndr.
2016;72(2):184–8.
21. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic
and immunologic heterogeneity among persons who control HIV infection
in the absence of therapy. J Infect Dis. 2008;197(4):563–71.
Moosa et al. BMC Infectious Diseases  (2018) 18:54 Page 6 of 7
22. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, et al.
Heterogeneous neutralizing antibody and antibody-dependent cell
cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009;23(8):897–906.
23. Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, et al.
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-
sensitive viruses in a viremic controller. Sci Transl Med. 2017;9(373):eaal2144.
24. Nakajima T, Kaur G, Mehra N, Kimura A. HIV-1/AIDS susceptibility and copy
number variation in CCL3L1, a gene encoding a natural ligand for HIV-1
co-receptor CCR5. Cytogenet Genome Res. 2008;123(1–4):156–60.
25. Riveira-Muñoz E, Ruiz A, Pauls E, Permanyer M, Badia R, Mothe B, et al.
Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. J
Antimicrob Chemother. 2014;69(11):3057–60.
26. Kikuchi T, Iwabu Y, Tada T, Kawana-Tachikawa A, Koga M, Hosoya N, et al.
Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
J Virol. 2015;89(9):4992–5001.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Moosa et al. BMC Infectious Diseases  (2018) 18:54 Page 7 of 7
